Opinion|Videos|August 13, 2024

Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

Experts give an overview of the ASCO 2024 data.

Video content above is prompted by the following question:

The phase 2 CORE-001 trial investigated a new treatment combination of intravesical cretostimogene grenadenorepvec with pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC. Before we review the trial background and results presented at the ASCO 2024 Annual Meeting, can you introduce cretostimogene and describe its mechanism of action?